PRODUCT DESCRIPTION:

Tenofovir Disoproxil Fumarate (TDF) Tablets 300 MG is a globally recognized nucleotide reverse transcriptase inhibitor (NRTI), used extensively in first-line antiretroviral therapy (ART) for HIV-1 infection and chronic Hepatitis B (HBV).

As a once-daily oral medication, TDF plays a critical role in reducing viral load and improving immune function. With its proven safety profile and WHO-preferred status, TDF is a mainstay in global HIV and HBV programs.

Our formulations are produced in WHO-GMP and regulatory-compliant facilities, making them suitable for global health tenders, humanitarian programs, and public health initiatives.

Formulation & Presentation:

• Dosage Form: Tablets
• Presentation: Available in Blister Pack or HDPE Bottle (As per market requirement)
• Available Strengths:
  • Tenofovir Disoproxil Fumarate Tablets: 300 MG
• Route of Administration: Oral (As per physician’s discretion or therapeutic indication)

Therapeutic Indications:

• Treatment of HIV-1 infection, in combination with other antiretrovirals
• Chronic Hepatitis B infection
• Used in post-exposure prophylaxis (PEP) in high-risk settings
• Core component in pre-exposure prophylaxis (PrEP) when used with Emtricitabine

Side Effects:

• COMMON:
  • Nausea
  • Diarrhea
  • Fatigue
  • Headache
  • Dizziness
  • Rash
• SERIOUS (RARE):
  • Lactic acidosis
  • Severe hepatomegaly with steatosis
  • Renal toxicity (Fanconi syndrome, proximal tubulopathy)
  • Decreased bone mineral density
  • Immune reconstitution syndrome
• PRECAUTIONS:
  • Monitor renal function periodically in long-term therapy
  • Use cautiously in patients with osteoporosis or bone risk factors
  • Avoid use with other nephrotoxic agents
  • Should not be used as monotherapy for HIV
  • Monitor liver enzymes in HBV co-infection, especially on discontinuation